Liu M A, McClements W, Ulmer J B, Shiver J, Donnelly J
Department of Virus and Cell Biology, Merck Research Laboratories, West Point, PA 19486, USA.
Vaccine. 1997 Jun;15(8):909-12. doi: 10.1016/s0264-410x(96)00280-0.
The pre-clinical efficacy of DNA vaccines has been demonstrated in a number of animal models, but more limited data exist regarding their immunogenicity in non-human primates. The studies described below demonstrate that DNA vaccines in reasonable dosages encoding a variety of viral proteins could result in the generation of antibodies, neutralizing antibodies, or cytotoxic T lymphocytes in primates. Furthermore, these responses could be boosted by repeat administration of the DNA vaccine. In an effort to assess the safety of such vaccines sera from primates was shown to lack anti-DNA antibodies.
DNA疫苗的临床前疗效已在多种动物模型中得到证实,但关于其在非人类灵长类动物中的免疫原性的数据则较为有限。以下所述研究表明,编码多种病毒蛋白的合理剂量的DNA疫苗可在灵长类动物中产生抗体、中和抗体或细胞毒性T淋巴细胞。此外,重复接种DNA疫苗可增强这些反应。为了评估此类疫苗的安全性,研究表明灵长类动物的血清中缺乏抗DNA抗体。